Scancell Holdings shares fell 27% this week, a sharp decline that masks a strategic pivot for the biotechnology firm.
The company is preparing to transfer its primary listing to the Nasdaq stock exchange, a move that signals a broader shift in capital markets for small-cap growth companies.
The share price drop reflects short-term volatility surrounding the delisting process and the associated costs of establishing a US presence.
However, the underlying narrative for investors remains focused on the long-term benefits of accessing deeper US liquidity pools and a more specialized investor base for biotech equities.
This transition underscores the continuing erosion of the London Stock Exchange's Aim market.
The number of companies listed on Aim has fallen to 612, a stark indicator of the challenges facing the UK's junior market.